cancer

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug Administration granted accelerated approval for…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug Administration granted regular approval to…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug Administration granted approval for lutetium…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a…

6 months ago

FDA grants approval to Nogapendekin alfa inbakicept-pmln for bladder cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 22, 2024, the U.S. Food and Drug Administration granted approval for nogapendekin…

6 months ago

Biomarker Testing in Cancer

By Dr. Dipesh Uprety Karmanos Cancer Institute   & Dr. Howard (Jack) West City of Hope   What is a…

1 year ago

FDA Approves Talazoparib and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer with HRR Gene Mutation

On June 20, 2023, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) in combination with enzalutamide for…

1 year ago

FDA Approves Enfortumab Vedotin with Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

On April 3, 2023, the U.S. Food and Drug Administration approved enfortumab vedontin-ejfv with pembrolizumab for patients with locally advanced…

2 years ago

The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer

By Dr. Inas Abuali Massachusetts General Hospital   There is a paucity of available treatment options for patients with advanced…

2 years ago

FDA Approves an Expanded Indication of Abemaciclib with Endocrine Therapy for Early Breast Cancer

On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for…

2 years ago